NODELMAN OLEG — SEC insider filings
SEC reporting owner CIK 1454385. 23 insider filings on record with FilingPulse; latest filed 2026-11-18.
Transaction summary — filings shown
Covers all 23 filings on record, filed 2021-02-12 to 2026-11-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 52 legs across 19 filings — 17,911,552 shares, $134,401,041 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 2 filings — 876,379 shares, $16,526,608 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 27.
- Largest priced transaction: purchase of 2,077,779 shares @ $18.00 ($37,400,022) in Aktis Oncology, Inc., filed 2026-01-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ANAPTYSBIO, INC (ANAB) | Director, 10% owner | 5 | 13 legs · 1,496,715 sh · $41,405,878 | 1 leg · 668,237 sh · $14,453,966 | — |
| Aktis Oncology, Inc. (AKTS) | Director | 1 | 2 legs · 2,222,222 sh · $39,999,996 | — | 10 |
| Zymeworks Inc. (ZYME) | Director, 10% owner | 9 | 20 legs · 2,163,747 sh · $26,071,310 | — | 3 |
| Nuvation Bio Inc. (NUVB) | Director | 6 | 16 legs · 11,483,868 sh · $21,473,857 | 2 legs · 208,142 sh · $2,072,642 | 13 |
| Panacea Acquisition Corp. II (PANA) | Director, 10% owner | 2 | 1 leg · 545,000 sh · $5,450,000 | — | 1 |
Insider filings — NODELMAN OLEG
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | ANAPTYSBIO, INC (ANAB) jointly with EcoR1 Capital, LLC | Purchase (P): 84,120 @ $45.66 · Purchase (P): 152,367 @ $45.66 · Purchase (P): 138,093 @ $46.54 | EDGAR |
| 2026-01-12 | 4 | Aktis Oncology, Inc. (AKTS) jointly with EcoR1 Capital, LLC | Conversion (C): 2,270,879 · Conversion (C): 202,862 · Conversion (C): 128,506 · Purchase (P): 2,077,779 @ $18 · Purchase (P): 144,443 @ $18 · Conversion (C): 9,913,810 (derivative) · +6 more | EDGAR |
| 2025-06-27 | 4 | Zymeworks Inc. (ZYME) jointly with EcoR1 Capital, LLC | Option exercise/expiry (X): 5,086,480 @ $0.00 · Tax withholding (F): 41 @ $12.71 · Option exercise/expiry (X): 5,086,521 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Zymeworks Inc. (ZYME) jointly with EcoR1 Capital, LLC | Purchase (P): 49,502 @ $11.43 · Purchase (P): 5,919 @ $11.78 | EDGAR |
| 2025-04-18 | 4 | Zymeworks Inc. (ZYME) jointly with EcoR1 Capital, LLC | Purchase (P): 73,953 @ $11.16 · Purchase (P): 54,760 @ $11.52 | EDGAR |
| 2025-04-07 | 4 | Zymeworks Inc. (ZYME) jointly with EcoR1 Capital, LLC | Purchase (P): 120,770 @ $11.84 · Purchase (P): 196,438 @ $11.17 | EDGAR |
| 2025-04-02 | 4 | Zymeworks Inc. (ZYME) jointly with EcoR1 Capital, LLC | Purchase (P): 4,397 @ $11.75 · Purchase (P): 48,658 @ $11.60 · Purchase (P): 74,360 @ $11.85 | EDGAR |
| 2025-03-27 | 4 | Zymeworks Inc. (ZYME) jointly with EcoR1 Capital, LLC | Purchase (P): 53,501 @ $12.91 · Purchase (P): 43,848 @ $12.24 | EDGAR |
| 2025-03-24 | 4 | Zymeworks Inc. (ZYME) jointly with EcoR1 Capital, LLC | Purchase (P): 73,476 @ $12.93 · Purchase (P): 31,033 @ $12.78 · Purchase (P): 22,689 @ $13.08 | EDGAR |
| 2025-03-19 | 4 | Zymeworks Inc. (ZYME) jointly with EcoR1 Capital, LLC | Purchase (P): 56,277 @ $12.23 · Purchase (P): 113,880 @ $12.65 · Purchase (P): 58,306 @ $12.64 | EDGAR |
| 2025-03-13 | 4 | Zymeworks Inc. (ZYME) jointly with EcoR1 Capital, LLC | Purchase (P): 320,690 @ $11.49 · Purchase (P): 292,934 @ $12.25 · Purchase (P): 468,356 @ $12.48 | EDGAR |
| 2025-01-02 | 4 | ANAPTYSBIO, INC (ANAB) jointly with EcoR1 Capital, LLC | Purchase (P): 65,184 @ $12.92 · Purchase (P): 13,268 @ $12.93 · Purchase (P): 6,646 @ $12.95 | EDGAR |
| 2023-09-22 | 4/A | Nuvation Bio Inc. (NUVB) jointly with EcoR1 Capital, LLC, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, Biotech Opportunity GP, LLC | Purchase (P): 5,143,000 @ $1.26 · Purchase (P): 117,100 @ $1.36 · Purchase (P): 53,000 @ $1.36 | EDGAR |
| 2023-09-21 | 4 | Nuvation Bio Inc. (NUVB) jointly with EcoR1 Capital, LLC, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, Biotech Opportunity GP, LLC | Purchase (P): 5,143,000 @ $1.26 · Purchase (P): 117,100 @ $1.36 · Purchase (P): 53,000 @ $1.36 | EDGAR |
| 2023-05-02 | 4 | Panacea Acquisition Corp. II (PANA) jointly with EcoR1 Panacea Holdings II, LLC, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, EcoR1 Capital, LLC, Biotech Opportunity GP, LLC | Disposition to issuer (D): 545,000 | EDGAR |
| 2022-05-09 | 4 | ANAPTYSBIO, INC (ANAB) jointly with EcoR1 Capital, LLC | Purchase (P): 668,237 @ $21.63 · Sale (S): 668,237 @ $21.63 | EDGAR |
| 2021-11-30 | 4 | Nuvation Bio Inc. (NUVB) jointly with EcoR1 Capital, LLC, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, Biotech Opportunity GP, LLC | Purchase (P): 151,544 @ $10.45 · Sale (S): 151,544 @ $10.45 · Purchase (P): 56,598 @ $8.64 · Sale (S): 56,598 @ $8.64 · Purchase (P): 163,268 @ $7.69 · Purchase (P): 21,758 @ $7.69 | EDGAR |
| 2021-11-02 | 4 | Nuvation Bio Inc. (NUVB) | Grant/award (A): 45,229 (derivative) @ $0 | EDGAR |
| 2021-05-04 | 4 | ANAPTYSBIO, INC (ANAB) jointly with EcoR1 Capital, LLC | Purchase (P): 35,700 @ $23.16 · Purchase (P): 20,800 @ $23.31 · Purchase (P): 165,000 @ $23.25 | EDGAR |
| 2021-04-27 | 4 | ANAPTYSBIO, INC (ANAB) jointly with EcoR1 Capital, LLC | Purchase (P): 99,600 @ $23.54 · Purchase (P): 13,900 @ $23.80 · Purchase (P): 33,800 @ $23.82 | EDGAR |
| 2021-04-13 | 4 | Panacea Acquisition Corp. II (PANA) jointly with EcoR1 Panacea Holdings II, LLC, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, EcoR1 Capital, LLC, Biotech Opportunity GP, LLC | Purchase (P): 545,000 @ $10 | EDGAR |
| 2021-04-13 | 4 | Nuvation Bio Inc. (NUVB) jointly with EcoR1 Capital, LLC, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, EcoR1 Panacea Holdings, LLC, Biotech Opportunity GP, LLC | Purchase (P): 262,230 @ $10.03 · Purchase (P): 37,770 @ $10.03 · Purchase (P): 116,255 @ $9.49 · Purchase (P): 16,745 @ $9.49 · Purchase (P): 27,534 @ $10.27 · Purchase (P): 3,966 @ $10.27 | EDGAR |
| 2021-02-12 | 4 | Nuvation Bio Inc. (NUVB) jointly with EcoR1 Panacea Holdings, LLC, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, EcoR1 Capital, LLC, Biotech Opportunity GP, LLC | Conversion (C): 2,775,000 @ $0 · Grant/award (A): 2,106,000 · Grant/award (A): 394,000 · Grant/award (A): 2,112,735 @ $10 · Grant/award (A): 387,265 @ $10 · Grant/award (A): 2,365,511 @ $0 · +6 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1454385 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs